TI-2: Integrative Immunogenetics and Cellular Approaches toward Developing an Antigen-Specific Therapy

Coordinators: P. Bacher (CAU), A. Scheffold (CAU)

The members of TI-2 want to identify potential triggers of chronic inflammatory bowel disease (IBD). The inflammation is maintained by immune cells so called T cells, which mistakenly target harmless intestinal components, for example parts of the microbiome or food components, and in this way lead to tissue damage. The researchers in TI-2 want to identify novel and patient-specific therapeutic targets and diagnostic opportunities with the aim of selectively switching off the disease-causing T cells.